Leading innovators are streamlining quality management across their organizations and with external partners
PLEASANTON, CA — Sept 12, 2018 — Modernizing quality management is becoming a top priority among leading life sciences companies. With this shift underway, an increasing number of organizations are unifying quality processes with Veeva Vault Quality applications from Veeva Systems (NYSE:VEEV). The number of Vault Quality customers has increased to more than 180, including 10 of the top 20 largest global pharmaceutical companies implementing Veeva Vault QualityDocs in at least one division. Also, the number of Veeva Vault QMS customers has nearly doubled since last year, with 58 life sciences organizations using the application to manage quality processes.
“Collaboration and access among global stakeholders are critical to compliance and driving operational alignment,” said Maria Conklin, associate director, quality control, at Karyopharm Therapeutics. “Veeva Vault Quality gives us unified applications to manage quality documents and processes across our organization and with partners on one cloud platform, making collaboration much more efficient and secure.”
Vault Quality applications help streamline business processes and content across global sites, suppliers, contract manufacturers, and other partners to speed workflows for greater efficiency. Vault QMS, Vault QualityDocs, and Vault Training are part of the Vault Quality Suite, bringing together quality processes, document control, and training on a single cloud platform.
“There is a significant opportunity for companies to modernize quality management and give internal and external teams greater visibility and transparency,” said Mike Jovanis, vice president of Vault Quality at Veeva. “With a cloud-based solution, organizations can more closely align with partners to operate effectively and meet compliance regulations with ease.”
Customers can also bring together Vault Quality suite with applications for clinical and regulatory as part of Veeva Development Cloud, a unified suite of applications that helps organizations drive end-to-end business processes across research and development and manufacturing.
In other news, Veeva announced that more medical devices and diagnostics companies are adopting Veeva Vault to streamline processes throughout the product lifecycle. Read today’s press release to learn more.
Also, join more than 1,300 life sciences professionals and experts at the upcoming Veeva R&D Summit in Philadelphia, September 16-18. Learn more, register, and view the full agenda at veeva.com/R&DSummit.
For more on Veeva Vault Quality Suite, visit: veeva.com/Quality
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.